IMPACT2: Monitoring Interventions to Improve Artemisinin-based Combination Therapy (ACT) Access and Targeting

IMPACT2: Monitoring Interventions to Improve ACT Access and Targeting

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01130155

Acronym

IMPACT2

Enrollment

33900

Registered

2010-05-25

Start date

2010-05-31

Completion date

2012-12-31

Last updated

2011-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaemia, Malaria

Keywords

Antimalarials, Diagnosis, Access to treatment, Quality of care

Brief summary

It is generally agreed that artemisinin-based combination therapy (ACT) is the malaria therapy of choice but there is much less agreement about the best ACT-deployment strategies. Countries are now beginning to adopt policies to enhance ACT deployment that aim to address 2 key goals: (i) making ACTs more readily and speedily accessible to patients: or (ii) targeting ACTs to patients shown to have malaria parasitaemia. The Tanzanian Government has secured funding to address both ACT access and targeting on a national scale. Access is to be improved through the distribution of subsidised ACTs through private facilities and retail drug shops under the Affordable Medicines Facility-malaria (AMFm). Targeting is to be addressed through enhancing microscopy and introducing rapid diagnostic tests (RDTs) in health facilities at every level of the system. This study will evaluate these two interventions in 3 rural regions of Tanzania which are all expected to receive both interventions during the study period. The investigators will assess the effectiveness of the interventions in terms of coverage, equity, quality, adherence, and public health impact using a pre-post plausibility design based on before and after household, health facility and outlet surveys. The null hypothesis is that the interventions will have no impact on the coverage of prompt effective treatment for fever and malarial. In addition, the investigators will estimate the cost and cost-effectiveness of implementation from a health system and household perspective. Finally the investigators will explore the socio-cultural context and other factors that influence the implementation and outcome of the interventions.

Interventions

None listed

Study design

Observational model

ECOLOGIC_OR_COMMUNITY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

3 Months to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Household survey - All consenting and assenting residents available in selected households * Health facility survey - patients presenting to selected health facilities with fever or history of fever in the prior 24 hours; Age \>= 3 months, or Weight ≥ 5 kg; First visit to this health facility for this illness episode

Exclusion criteria

* Household survey - Children less than 3 months of age will be excluded from providing a blood sample * Health facility survey - Signs of severe illness

Design outcomes

Primary

Measure	Time frame
Proportion of patients presenting to public health facilities with fever who receive rapid diagnostic test (RDT) for malaria and are appropriately treated according to RDT results	—
Percent of population reporting fever in last two weeks that got a finger/heel stick for a malaria diagnostic test within 24hrs/48hrs	—
Percent of population reporting fever in last two weeks that received ACT within 24hrs/48hrs	—
Proportion of patients presenting to public health facilities with fever who receive a diagnostic test for malaria	—

Secondary

Measure	Time frame
Percent of patients receiving an ACT that adhered to full dose with correct dose timing	—
Mean and median household cost per febrile episode	—
The accuracy of RDTs performed by health workers	—
Adequacy of health facility resources for diagnosis and treatment of malaria	—

Countries

Tanzania

Outcome results